When C5a and Tgfβ1 are highly expressed in Neuro-PASC patients they may benefit from treatment with existing drugs on the market and in late development targeting C5a and Tgfβ1, and the target and patient symptoms monitored. This evidence concerns the gene C5AR1 and long COVID-19.